Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Harvard University), Christopher L. Corless(Oregon Health & Science University), Brian Druker(Oregon Health & Science University), Charles D. Blanke(SWOG Cancer Research Network), Christopher D.�M. Fletcher(Brigham and Women's Hospital), George D. Demetri(Dana-Farber Cancer Institute), Samuel Singer(Memorial Sloan Kettering Cancer Center), Annick D. Van den Abbeele(Unknown), Peter Roberts(University of Bristol), Sandra Silberman(Novartis (Switzerland)), Margaret von Mehren(Temple University Health System), Burton Eisenberg(Hoag Memorial Hospital Presbyterian), Heikki Joensuu(Orion Corporation (Finland)), Changjie Chen(Bengbu Medical College), Laura McGreevey(Novartis (Switzerland)), Saša Dimitrijević(Novartis (Switzerland)), Beate Kiese(Novartis (Switzerland))
Cited by 145
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k